Tom C Chou, 79Huntington Beach, CA

4887205, Dec 12, 1989

Jul 1, 1987

7/065191

Tom M. Chou - San Clemente CA

E05F 1510
E05F 1520
H02P 122
H02P 104

364400

A system for controlling a gate includes a microprocessor which normally automatically recloses a gate after it has been opened in response to a radio or sensor loop signal, and which normally locks the gate against movement when the gate motor is stopped. When an obstruction is sensed in the path of the gate, the automatic reclosing feature and the sensor loops are disabled, the gate drive remains unlocked even though the motor is stopped, and the response of the system to a radio signal is changed to produce alternating opening and closing of the gate on successive radio signals. At all times, the gate drive lock is released before the motor is started and is not engaged until after the gate has come to rest. Field adjustment of the obstruction sensor is avoided by generating an obstruction signal only when the gate speed falls below the operating speed of a gate imposing the largest design load on the motor, and the speed at which an obstruction is sensed is adjustable in discrete increments by digital switches so that the specific load level at which the system sees an obstruction may be selected to fit various conditions.

2015012, May 7, 2015

Mar 15, 2013

14/385824

- Oakland CA, US
Kelechi Chikere - Los Angeles CA, US
Tom Chou - Venice CA, US

C12Q 1/66
C12N 5/071

435 5, 435369, 4353201, 435455

The invention pertains to a novel cell line, an HIV tat-rev dependent GFP-Gaussia luciferase Reporter cell line, known henceforth as the GGR cell line, that detects pseudotype and replication competent HIV (cloned or uncloned isolates, in cell media or human serum) rapidly and with high sensitivity. This GGR cell line provides an improved method of characterizing the entry phenotype of HIV envelope genes, and detecting and examining primary HIV samples in the context of laboratory research, clinical trial monitoring, and medical diagnostics. Examples include, but are not limited to, determining the functional HIV viral load, responsiveness to treatment, characterization of viral co-receptor usage (testing for viral co-receptor usage, i.e., CCR5 vs CXCR4, as required prior to prescribing FDA-approved CCR5 inhibitors), and characterization of other viral or drug resistance phenotypic properties to guide treatment.